MRVI Stock Overview
Maravai LifeSciences Holdings, Inc. es una empresa de ciencias de la vida que suministra productos que permiten el desarrollo de terapias farmacológicas, diagnósticos, vacunas novedosas y apoyan la investigación de enfermedades humanas en todo el mundo.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Maravai LifeSciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.95 |
| 52 Week High | US$16.62 |
| 52 Week Low | US$4.52 |
| Beta | 0.0060 |
| 1 Month Change | 3.65% |
| 3 Month Change | 19.37% |
| 1 Year Change | -42.97% |
| 3 Year Change | -77.27% |
| 5 Year Change | n/a |
| Change since IPO | -73.37% |
Recent News & Updates
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Recent updates
An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 29Maravai Faces Skeptical Investors As Pandemic Enters New Period
Jan 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk
Dec 02Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 26% Below Its Share Price
Oct 07Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Worth US$41.7 Based On Its Intrinsic Value?
Jul 01Maravai LifeSciences: The Future Beyond Covid Vaccines
Jun 29Need To Know: Analysts Are Much More Bullish On Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
May 13Shareholder Returns
| MRVI | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -7.6% | -1.6% | -0.8% |
| 1Y | -43.0% | 0.6% | 25.9% |
Rentabilidad frente al sector: MRVI obtuvo unos resultados inferiores a los del sector US Life Sciences , que el año pasado arrojó un rendimiento del -13.4%.
Rentabilidad vs. Mercado: MRVI obtuvo unos resultados inferiores a los del mercado US, que fue del 14.1% el año pasado.
Price Volatility
| MRVI volatility | |
|---|---|
| MRVI Average Weekly Movement | 19.9% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: MRVIha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: MRVILa volatilidad semanal ha pasado de 13% a 20% en el último año.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 650 | Trey Martin | https://www.maravai.com |
Maravai LifeSciences Holdings, Inc. es una empresa de ciencias de la vida que suministra productos que permiten el desarrollo de terapias farmacológicas, diagnósticos, vacunas novedosas y apoyan la investigación de enfermedades humanas en todo el mundo. Los productos de la empresa abordan las fases clave del desarrollo biofarmacéutico e incluyen ácidos nucleicos para aplicaciones diagnósticas y terapéuticas, productos basados en anticuerpos para detectar impurezas durante la producción de productos biofarmacéuticos y productos para detectar la expresión de proteínas en tejidos de diversas especies. Opera en dos segmentos, Producción de Ácidos Nucleicos y Pruebas de Seguridad Biológica.
Maravai LifeSciences Holdings, Inc. Fundamentals Summary
| MRVI fundamental statistics | |
|---|---|
| Market cap | US$2.00b |
| Earnings (TTM) | -US$119.03m |
| Revenue (TTM) | US$288.95m |
3.6x
P/S Ratio-8.8x
P/E RatioIs MRVI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVI income statement (TTM) | |
|---|---|
| Revenue | US$288.95m |
| Cost of Revenue | US$148.74m |
| Gross Profit | US$140.20m |
| Other Expenses | US$259.23m |
| Earnings | -US$119.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 48.52% |
| Net Profit Margin | -41.19% |
| Debt/Equity Ratio | 66.4% |
How did MRVI perform over the long term?
See historical performance and comparison